Efficacy of an integrative treatment (Personalised Integrative Therapy) for depression and / or anxiety in adults: a randomised controlled pilot trial

Murdoch University0 sites48 target enrollmentMarch 19, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 19, 2019

End Date

August 30, 2019

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Adults (male and female) aged between 18 and 65 years
•2\. Self\-reported mild\-to\-moderate depression and/or anxiety as assessed by the DASS
•3\. Fluent in English
•4\. Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the trial.
•5\. Willing and able to participate in this 12\-week study (6 active weeks plus 6\-week follow\-up)
•6\. If taking pharmaceutical medications (including antidepressants) must be on a stable dose for the last 8\-weeks. All participants should continue to take their pharmaceutical medications as prescribed by their treating doctor during the trial.

•1\. DSM\-5 diagnosis including but not limited to bipolar disorder, schizophrenia, psycho\-organic syndromes, eating disorders, substance abuse or dependence disorders.
•2\. At significant risk of suicide or engaging in self\-harm behaviours.
•3\. Suffering from major medical illness impacting on ability to implement many lifestyle, dietary, and psychological changes covered in the program. Medical disorders include but are not limited to cancers, serious cardiovascular disease, neurodegenerative disorders (e.g., Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease), and unmanaged metabolic disorders such as diabetes.
•4\. Currently receiving psychological therapy for depression or anxiety by a mental health practitioner
•5\. Currently taking greater than 2 natural supplements that are included in the PI \+ supplements condition
•6\. Known allergy or significant intolerance to natural supplements